TheraRadar
Landscape → Oncology

Endometrial Cancer Clinical Trial Landscape

Data updated: May 20, 2026

448 clinical trials tracked since 2008

Endometrial Cancer is being studied across 448 clinical trials registered since 2008, with 238 programs currently active. The competitive pipeline includes 32 active Phase 3 trials, 139 active Phase 2 trials, and 111 active Phase 1 trials. Top industry sponsors include AstraZeneca, Merck, Genmab.

238 active
/
448 total (since 2008)
111
Phase 1 Active
206 total
139
Phase 2 Active
268 total
32
Phase 3 Active
48 total
4
Phase 4 Active
11 total

Top Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 8 1 0
Merck 3 2 0
Genmab 2 1 4
Xencor, Inc. 2 3 0
Daiichi Sankyo 2 1 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT07198074 RECRUITING
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI) n=255
NCT05256225 RECRUITING
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI) n=360
NCT06952504 RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Merck Sharp & Dohme LLC n=1,123
NCT07166094 RECRUITING
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Genmab n=660
NCT06989112 RECRUITING
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
AstraZeneca n=600

+ 43 more Phase 3 trials — see full database below

Endometrial Cancer — Trials Started by Year (last 10 years)

2016
18
2017
20
2018
26
2019
30
2020
27
2021
35
2022
37
2023
46
2024
55
2025
44
2026
26

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

AstraZeneca
9
Merck
5
Genmab
7
Xencor, Inc.
5
Daiichi Sankyo
3
NextCure, Inc.
3
Regeneron
2
Radiopharm Theranostics, Ltd
2
Whitehawk Therapeutics, Inc.
2
SystImmune Inc.
2

Active Trials by Phase

Phase 1
111
Phase 2
139
Phase 3
32
Phase 4
4

Enrollment Size Distribution

1-50
180
51-200
154
201-500
58
501-1k
28
1k+
7

All Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 8 1 0
Merck 3 2 0
Genmab 2 1 4
Xencor, Inc. 2 3 0
Daiichi Sankyo 2 1 0
NextCure, Inc. 2 1 0
Regeneron 2 0 0
Radiopharm Theranostics, Ltd 2 0 0
Whitehawk Therapeutics, Inc. 2 0 0
SystImmune Inc. 2 0 0
MacroGenics 2 0 0
Evergreen Therapeutics, Inc. 2 0 0
GV20 Therapeutics 2 0 0
Incyte Corporation 1 3 2
Novartis 1 3 1
NCT07198074 RECRUITING
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI) n=255
NCT05256225 RECRUITING
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI) n=360
NCT07578649 NOT YET RECRUITING
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Pfizer n=600
NCT06952504 RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Merck Sharp & Dohme LLC n=1,123
NCT07166094 RECRUITING
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Genmab n=660
NCT06989112 RECRUITING
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
AstraZeneca n=600
NCT03914612 ACTIVE NOT RECRUITING
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI) n=813
NCT06340568 RECRUITING
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
BioNTech SE n=480
NCT05611931 RECRUITING
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics Inc n=276
NCT03785288 RECRUITING
Vaginal Cuff Brachytherapy Fractionation Study
Kara Romano, MD n=258
NCT06746116 ACTIVE NOT RECRUITING
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
AstraZeneca n=45
NCT07044336 RECRUITING
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca n=700
NCT06132958 ACTIVE NOT RECRUITING
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Merck Sharp & Dohme LLC n=710
NCT04789694 RECRUITING
Prehabilitation in Gynaecological Cancer Patients
Charles University, Czech Republic n=64
NCT07319429 RECRUITING
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
Fudan University n=260
NCT07022483 RECRUITING
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo n=710
NCT04073706 RECRUITING
Sentinel Node Biopsy in Endometrial Cancer
Queensland Centre for Gynaecological Cancer n=760
NCT06712472 RECRUITING
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=554
NCT06486441 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Gilead Sciences n=640
NCT05077215 NOT YET RECRUITING
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Evergreen Therapeutics, Inc. n=450
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT05201547 ACTIVE NOT RECRUITING
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
ARCAGY/ GINECO GROUP n=260
NCT05316467 RECRUITING
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Xiaojun Chen n=89
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT06584032 RECRUITING
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed n=412
NCT05255653 RECRUITING
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
Leiden University Medical Center n=1,615
NCT06475599 NOT YET RECRUITING
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=420
NCT05797831 RECRUITING
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Kartos Therapeutics, Inc. n=268
NCT03469674 ACTIVE NOT RECRUITING
PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer
Leiden University Medical Center n=550
NCT05524389 NOT YET RECRUITING
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
Peking Union Medical College Hospital n=624
NCT05489848 NOT YET RECRUITING
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
Fudan University n=294
NCT03463252 RECRUITING
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
West China Second University Hospital n=224
NCT03555422 COMPLETED
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
Karyopharm Therapeutics Inc n=263
NCT05454358 TERMINATED
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Fudan University n=12
NCT06007586 COMPLETED
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute n=143
NCT06321068 TERMINATED
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Bio-Thera Solutions n=5
NCT04159155 TERMINATED
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
University Health Network, Toronto n=11
NCT03603184 COMPLETED
Atezolizumab Trial in Endometrial Cancer - AtTEnd
Mario Negri Institute for Pharmacological Research n=549
NCT06732635 COMPLETED
Enhanced Recovery After Surgery (ERAS) for Laparoscopic Hysterectomy at Low Risk Endometrial Cancer
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia n=68
NCT04849858 TERMINATED
Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
University of California, Irvine n=13
NCT04970368 TERMINATED
Comparison of Nodal Staging in Endometrial Cancer
Frederick R. Ueland, M.D. n=38
NCT05712941 WITHDRAWN
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
EQRx International, Inc.
NCT01470677 COMPLETED
Tachosil for the Prevention of Symptomatic Lymph Cysts
Ruhr University of Bochum n=220
NCT01672892 COMPLETED
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
Radiation Therapy Oncology Group n=289
NCT04237090 COMPLETED
Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
Ciusss de L'Est de l'Île de Montréal n=27
NCT03285802 COMPLETED
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
Greater Baltimore Medical Center n=1
NCT01767155 COMPLETED
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
AEterna Zentaris n=511
NCT00883116 TERMINATED
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
R-Pharm n=551

Full Endometrial Cancer Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only